PT3209651T - Derivados de carbazol - Google Patents

Derivados de carbazol

Info

Publication number
PT3209651T
PT3209651T PT157904087T PT15790408T PT3209651T PT 3209651 T PT3209651 T PT 3209651T PT 157904087 T PT157904087 T PT 157904087T PT 15790408 T PT15790408 T PT 15790408T PT 3209651 T PT3209651 T PT 3209651T
Authority
PT
Portugal
Prior art keywords
carbazole derivatives
carbazole
derivatives
Prior art date
Application number
PT157904087T
Other languages
English (en)
Portuguese (pt)
Inventor
Ahmad Saleem
G Batt Douglas
Liu Qingjie
E Macor John
A Tino Joseph
Hunter Watterson Scott
Kesavan Nair Satheesh
Kumar Maishal Tarun
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54427879&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3209651(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PT3209651T publication Critical patent/PT3209651T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
PT157904087T 2014-10-24 2015-10-23 Derivados de carbazol PT3209651T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462068234P 2014-10-24 2014-10-24

Publications (1)

Publication Number Publication Date
PT3209651T true PT3209651T (pt) 2019-12-30

Family

ID=54427879

Family Applications (1)

Application Number Title Priority Date Filing Date
PT157904087T PT3209651T (pt) 2014-10-24 2015-10-23 Derivados de carbazol

Country Status (33)

Country Link
US (3) US10266491B2 (fr)
EP (1) EP3209651B9 (fr)
JP (1) JP6599983B2 (fr)
KR (1) KR102514914B1 (fr)
CN (1) CN107074804B (fr)
AR (1) AR102427A1 (fr)
AU (1) AU2015335703B2 (fr)
BR (1) BR112017007545A2 (fr)
CA (1) CA2965523A1 (fr)
CL (1) CL2017001001A1 (fr)
CO (1) CO2017004517A2 (fr)
CY (1) CY1122549T1 (fr)
DK (1) DK3209651T3 (fr)
EA (1) EA032361B1 (fr)
ES (1) ES2761903T3 (fr)
HR (1) HRP20192197T2 (fr)
HU (1) HUE048321T2 (fr)
IL (1) IL251798B (fr)
LT (1) LT3209651T (fr)
MA (1) MA40302B1 (fr)
ME (1) ME03754B (fr)
MX (1) MX2017005255A (fr)
MY (1) MY190568A (fr)
PE (1) PE20171239A1 (fr)
PH (1) PH12017500724A1 (fr)
PL (1) PL3209651T3 (fr)
PT (1) PT3209651T (fr)
RS (1) RS59707B1 (fr)
SG (2) SG10201903619YA (fr)
SI (1) SI3209651T1 (fr)
TN (1) TN2017000158A1 (fr)
TW (1) TWI676618B (fr)
WO (1) WO2016065236A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017004629A (es) 2014-10-24 2017-06-30 Takeda Pharmaceuticals Co Compuesto heterociclico.
BR112017007563A2 (pt) * 2014-10-24 2017-12-19 Bristol Myers Squibb Co compostos atropisômeros tricíclicos
WO2018009017A1 (fr) * 2016-07-07 2018-01-11 Daewoong Pharmaceutical Co., Ltd. Nouveaux dérivés de 4-aminopyrazolo [3,4-d] pyrimidinylazabicyclo et compositions pharmaceutiques les contenant
GB201616627D0 (en) 2016-09-30 2016-11-16 Mission Therapeutics Limited Novel compounds
EP3694528A4 (fr) 2017-10-13 2021-07-28 The Regents of the University of California Modulateurs de mtorc1
CN109053542A (zh) * 2018-07-25 2018-12-21 南通大学 一种6-溴-5-羟基异吲哚啉-1-酮的化学合成方法
CN110862396B (zh) * 2019-11-29 2021-06-04 浙江工业大学 一种吡咯并[3,4-c]咔唑-1,3(2H，6H)-二酮类化合物的合成方法
WO2021247748A1 (fr) * 2020-06-02 2021-12-09 Gb005, Inc. Inhibiteurs de kinases
CN115232061B (zh) * 2021-09-18 2024-01-30 山西紫罗蓝新材料科技有限公司 一种3-硝基-9-乙基咔唑粗产物的提取工艺
WO2024010784A1 (fr) * 2022-07-06 2024-01-11 Vividion Therapeutics, Inc. Compositions pharmaceutiques comprenant des inhibiteurs de l'hélicase wrn
WO2024073587A1 (fr) * 2022-09-29 2024-04-04 Vividion Therapeutics, Inc. Dérivés de n-acryloylmorpholine utilisés en tant que modulateurs de keap1 et utilisations associées

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4200750A (en) 1977-01-07 1980-04-29 Westwood Pharmaceuticals Inc. 4-Substituted imidazo [1,2-a]quinoxalines
CA2140722A1 (fr) 1994-01-24 1995-07-25 Joseph A. Jakubowski Beta-carboline-thromboxane-synthetase
WO2005014599A1 (fr) 2003-06-04 2005-02-17 Cellular Genomics, Inc. Imidazo[1,2-a]pyrazin-8-ylamines et methodes d'inhibition de la tyrosine kinase de bruton par de tels composes
US7393848B2 (en) 2003-06-30 2008-07-01 Cgi Pharmaceuticals, Inc. Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds
WO2005047290A2 (fr) 2003-11-11 2005-05-26 Cellular Genomics Inc. Certaines imidazo[1,2-a]pyrazin-8-ylamines, procede de fabrication et methode d'utilisation
WO2006044687A2 (fr) 2004-10-15 2006-04-27 Takeda San Diego, Inc. Inhibiteurs de kinase
CA2587192A1 (fr) 2004-11-10 2006-05-18 Cgi Pharmaceuticals, Inc. Certaines imidazo[1,2-a] pyrazin-8-ylamines et les procedes de fabrication et d'utilisation correspondants
PL1831227T3 (pl) 2004-12-17 2013-10-31 Glenmark Pharmaceuticals Sa Nowe związki heterocykliczne użyteczne w leczeniu stanów zapalnych i dolegliwości alergicznych
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
ES2390135T3 (es) * 2005-11-22 2012-11-06 Merck Sharp & Dohme Corp. Compuestos tricíclicos útiles como inhibidores de quinasas
JP2010502751A (ja) 2006-09-11 2010-01-28 シージーアイ ファーマシューティカルズ，インコーポレイティド キナーゼ阻害物質、およびキナーゼ阻害物質の使用および同定方法
RU2009113585A (ru) 2006-09-11 2010-10-20 Матрикс Лэборетериз Лтд. (In) Производные дибензофурана в качестве ингибиторов pde-4 и pde-10
US20090062251A1 (en) 2007-08-17 2009-03-05 Astrazeneca Ab Novel Compounds 002
US7989465B2 (en) 2007-10-19 2011-08-02 Avila Therapeutics, Inc. 4,6-disubstituted pyrimidines useful as kinase inhibitors
WO2009075830A1 (fr) 2007-12-13 2009-06-18 Merck & Co., Inc. Inhibiteurs de janus kinases
DK2247558T3 (da) 2008-02-14 2022-02-21 Lilly Co Eli Nye billeddannelsesmidler til detektering af neurologisk dysfunktion
GB0809360D0 (en) 2008-05-22 2008-07-02 Isis Innovation Calcium modulation
JP2011524893A (ja) 2008-06-18 2011-09-08 ファイザー・リミテッド ニコチンアミド誘導体
MX360970B (es) 2008-06-27 2018-11-23 Avila Therapeutics Inc Compuestos de heteroarilo y usos de los mismos.
EP2151441A1 (fr) 2008-08-06 2010-02-10 Julius-Maximilians-Universität Würzburg Dérivés de béta-carboline en tant que substrats pour une enzyme
CA2747670A1 (fr) * 2008-12-19 2010-07-15 Bristol-Myers Squibb Company Composes carbazole carboxamide utiles comme inhibiteurs de kinases
CN101475571B (zh) 2009-01-21 2011-06-22 中国药科大学 β-咔啉类细胞周期蛋白依赖性激酶2抑制剂及其用途
WO2010093949A2 (fr) 2009-02-13 2010-08-19 Nextivity, Inc. Commande à distance d'un préamplificateur
US8685969B2 (en) 2010-06-16 2014-04-01 Bristol-Myers Squibb Company Carboline carboxamide compounds useful as kinase inhibitors
EP2455378A1 (fr) 2010-11-03 2012-05-23 Philip Morris Products S.A. Dérivés de carbazole et de carboline, et préparation et applications thérapeutiques associées
CA2817896A1 (fr) 2010-11-15 2012-05-24 Viiv Healthcare Uk Limited Inhibiteurs de la replication du vih
JP5859640B2 (ja) 2011-05-17 2016-02-10 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ブルトンチロシンキナーゼ阻害剤
WO2013106535A1 (fr) 2012-01-10 2013-07-18 Nimbus Iris, Inc. Inhibiteurs d'irak et leurs utilisations
MX2015002975A (es) 2012-10-26 2015-06-22 Hoffmann La Roche Inhibidores de la tirosina cinasa de bruton.
MX2015016771A (es) * 2013-06-25 2016-03-31 Squibb Bristol Myers Co Compuestos de carbazol carboxamida utiles como inhibidores de cinasa.
TWI648272B (zh) * 2013-06-25 2019-01-21 美商必治妥美雅史谷比公司 經取代之四氫咔唑及咔唑甲醯胺化合物
TWI744218B (zh) 2014-10-24 2021-11-01 美商必治妥美雅史谷比公司 吲哚甲醯胺化合物
BR112017007563A2 (pt) * 2014-10-24 2017-12-19 Bristol Myers Squibb Co compostos atropisômeros tricíclicos

Also Published As

Publication number Publication date
TWI676618B (zh) 2019-11-11
AU2015335703A1 (en) 2017-06-08
WO2016065236A1 (fr) 2016-04-28
SG10201903619YA (en) 2019-05-30
US20190225583A1 (en) 2019-07-25
DK3209651T3 (da) 2020-02-03
JP6599983B2 (ja) 2019-10-30
HRP20192197T2 (hr) 2020-11-13
US10266491B2 (en) 2019-04-23
KR20170075756A (ko) 2017-07-03
CL2017001001A1 (es) 2017-11-24
HUE048321T2 (hu) 2020-07-28
EA201790745A1 (ru) 2017-08-31
US20170362176A1 (en) 2017-12-21
CN107074804B (zh) 2020-02-18
IL251798B (en) 2020-08-31
HRP20192197T8 (hr) 2020-04-03
MY190568A (en) 2022-04-27
CY1122549T1 (el) 2021-01-27
PE20171239A1 (es) 2017-08-24
CA2965523A1 (fr) 2016-04-28
US20200255377A1 (en) 2020-08-13
TW201629014A (zh) 2016-08-16
MX2017005255A (es) 2017-08-18
US11053197B2 (en) 2021-07-06
SI3209651T1 (sl) 2019-12-31
LT3209651T (lt) 2020-01-10
MA40302B1 (fr) 2018-10-31
AU2015335703B2 (en) 2020-05-21
US10676434B2 (en) 2020-06-09
RS59707B1 (sr) 2020-01-31
AR102427A1 (es) 2017-03-01
TN2017000158A1 (en) 2018-10-19
CO2017004517A2 (es) 2017-08-31
JP2017535536A (ja) 2017-11-30
MA40302A1 (fr) 2018-05-31
PL3209651T3 (pl) 2020-03-31
BR112017007545A2 (pt) 2017-12-19
HRP20192197T1 (hr) 2020-03-06
EP3209651A1 (fr) 2017-08-30
SG11201703187PA (en) 2017-05-30
KR102514914B1 (ko) 2023-03-27
EP3209651B9 (fr) 2020-05-20
EP3209651B1 (fr) 2019-10-23
EA032361B1 (ru) 2019-05-31
ME03754B (fr) 2021-04-20
PH12017500724A1 (en) 2017-10-09
CN107074804A (zh) 2017-08-18
IL251798A0 (en) 2017-06-29
ES2761903T3 (es) 2020-05-21

Similar Documents

Publication Publication Date Title
HRP20192197T1 (hr) Derivati karbazola
SG11201609205WA (en) Heterocyclyl-butanamide derivatives
PT3131898T (pt) Derivados de fluoroalquilfluoreno
PL3418273T3 (pl) Pochodne flawaglin
IL248773A0 (en) History of naphthyridinedione
IL248629A0 (en) Substances containing diheteroaryl conjugated to cycloalkyl and their uses
LT3097076T (lt) Nauji cip-eikozanoidų dariniai
PL3119744T3 (pl) Pochodne 2-cyjano-3-cyklopropylo-3-hydroksy-N-arylo-tioakryloamidu
HUE042659T2 (hu) Ciklohexil-piridin származék
HK1243705A1 (zh) 吲哚衍生物